H. Kaul

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial

M. Dietlein, C. Kobe, P. Borchmann, 2022, BMC cancer.

Impact of bone marrow involvement on early positron emission tomography response and progression‐free survival in the HD18 trial for patients with advanced‐stage Hodgkin lymphoma

V. Diehl, T. Pabst, M. Dietlein, 2021, British journal of haematology.

Role of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial

M. Dietlein, P. Borchmann, A. Engert, 2022, 60. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin.

Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial

C. Kobe, P. Borchmann, A. Engert, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma

M. Hallek, J. Dierlamm, C. Lehmann, 2022, Infection.

P063: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial

C. Kobe, P. Borchmann, A. Engert, 2022, HemaSphere.

Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma

M. Hallek, J. Dierlamm, C. Lehmann, 2022, Infection.

Human leukocyte antigen (HLA) class I expression on Hodgkin–Reed–Sternberg cells is an EBV‐independent major determinant of microenvironment composition in classic Hodgkin lymphoma

P. Borchmann, A. Plütschow, P. Bröckelmann, 2024, HemaSphere.

Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early‐stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial

M. Dietlein, C. Kobe, P. Borchmann, 2023, European journal of haematology.

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial

M. Dietlein, C. Kobe, P. Borchmann, 2022, BMC Cancer.